Perspective Therapeutics Inc (CATX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 06-2022 | |
| Sales | 884 | 1,454 | 1,434 | 0 | 0 |
| Gross Profit | 884 | 1,454 | 1,434 | N/A | N/A |
| Operating Expenses | 114,448 | 92,340 | 42,375 | 0 | 6,419 |
| Operating Income | -113,564 | -90,886 | -40,941 | N/A | -6,419 |
| Interest Expense | 376 | 48 | 82 | 0 | 0 |
| Other Income | 9,512 | 10,507 | 917 | 0 | -853 |
| Pre-tax Income | -104,428 | -80,427 | -40,106 | 0 | -7,272 |
| Net Income Continuous | -104,428 | -80,427 | -40,106 | N/A | -7,272 |
| Net Income Discontinuous | 514 | -949 | -9,053 | N/A | N/A |
| Net Income Extraordinary | 793 | 2,097 | 2,651 | N/A | N/A |
| Net Income | $-103,121 | $-79,279 | $-46,508 | $N/A | $-7,272 |
| EPS Basic Total Ops | -1.40 | -1.23 | -1.74 | N/A | -0.50 |
| EPS Basic Continuous Ops | -1.41 | -1.22 | -1.40 | N/A | -0.40 |
| EPS Basic Discontinuous Ops | 0.01 | -0.01 | -0.34 | N/A | -0.10 |
| EPS Diluted Total Ops | -1.40 | -1.23 | -1.74 | N/A | -0.50 |
| EPS Diluted Continuous Ops | -1.41 | -1.22 | -1.40 | N/A | -0.40 |
| EPS Diluted Discontinuous Ops | 0.01 | -0.01 | -0.34 | N/A | -0.10 |
| EPS Diluted Before Non-Recurring Items | -1.41 | -0.85 | -1.40 | -0.50 | N/A |
| EBITDA(a) | $-113,036 | $-65,125 | $-39,955 | $N/A | $-6,139 |